Changes in Adipose Tissue With Lack of Insulin, IGF-1 Receptors

Share this content:
Changes in Adipose Tissue With Lack of Insulin, IGF-1 Receptors
Changes in Adipose Tissue With Lack of Insulin, IGF-1 Receptors

MONDAY, May 23, 2016 (HealthDay News) -- Mice lacking either the insulin receptor (IR), insulin-like growth factor 1 receptor (IGF1R), or both have disruptions in white and brown adipose tissue (WAT and BAT) formation, with an almost complete absence of WAT and BAT in mice lacking both receptors, according to a study published online May 13 in Diabetes.

Jeremie Boucher, Ph.D., from Harvard Medical School in Boston, and colleagues used Cre-recombinase driven by the adiponectin promoter to create mice lacking IR, IGF1R, or both.

The researchers found that mice lacking IGF1R only (F-IGFRKO) had about a 25 percent reduction in WAT and BAT. An almost complete absence of WAT and BAT was seen in mice lacking both IR and IGF1R (F-IR/IGFRKO). A 95 percent reduction in WAT was seen for F-IRKO mice, but they had a 50 percent increase in BAT with accumulation of large unilocular lipid droplets. F-IRKO and F-IR/IGFRKO mice were unable to maintain body temperature in the cold; they also developed severe diabetes, ectopic lipid accumulation in liver and muscle, and pancreatic islet hyperplasia. In both groups, leptin treatment normalized blood glucose levels. By 1 year of age, glucose levels also improved spontaneously, despite sustained lipodystrophy and insulin resistance.

"Loss of IR is sufficient to disrupt white fat formation, but not brown fat formation and/or maintenance, although it is required for normal BAT function and temperature homeostasis," the authors write.

One author was an employee of AstraZeneca R&D.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »